FRACTYL HEALTH, INC. (GUTS)

The company is a clinical stage metabolic therapeutics company focused on novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic disease, with the aim of moving treatment from chronic management toward prevention and reversion. The company's approach is built on over a decade of research implicating the gut and pancreas as targets in these diseases.

Its lead candidate, the Revita DMR System, remodels the duodenal lining through hydrothermal ablation (duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling. Revita has FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 based therapy. The company has received favorable FDA feedback on its De Novo classification request and anticipates submitting a De Novo marketing application in late fourth quarter of 2026. Revita is being evaluated in the REMAIN-1 program, which has three cohorts under a single IDE: REVEAL-1 (n=22, open-label), a Midpoint Cohort (n=45, randomized, double-blind, sham-controlled pilot) and a Pivotal Cohort (n=315, randomized, double-blind, sham-controlled). Enrollment is complete for all three cohorts. Revita has been evaluated in over 500 participants at sites in South America, Europe and the U.S. The second platform, Rejuva, is an AAV-delivered pancreatic gene therapy designed to reprogram pancreatic islet cells to produce metabolic hormones. Its lead candidate, RJVA-001, is intended to be delivered to the pancreas by a single endoscopic intervention so that beta cells express GLP-1 locally. RJVA-002, a dual GIP/GLP-1 gene therapy for obesity, is in preclinical development. Rejuva has been tested in animal models and in ex vivo murine and human islets, and the company describes the platform as modular and extendable to other metabolic targets.

The company targets people with obesity, prediabetes and T2D. It cites CDC data that about 115 million people in the U.S. have prediabetes and/or obesity and about 27 million have T2D. Its initial focus is patients who need to maintain weight loss after stopping GLP-1 drugs, which have high discontinuation rates and frequent weight regain. If Revita is approved in the U.S., the company plans a "hub-and-spoke" commercialization strategy with a targeted sales force working with GI endoscopists interested in bariatric and metabolic endoscopy. It also plans to draw on learnings from a commercial pilot in Germany and a letter of intent with Everself (formerly Bariendo), and to seek coverage and reimbursement from CMS and private insurers. Other stakeholders it addresses are referring physicians, providers and payors.

The company relies on clinical studies and a novel investigational pancreatic delivery device for Rejuva. It states that it holds issued patents and pending applications protecting core elements of its technology. Its leadership team has over 150 years of collective experience in therapeutic development, and it collaborates with expert advisors in metabolic disease, endoscopy and gene therapy. Competition discussed in the text centers on GLP-1 receptor agonist drugs such as tirzepatide and semaglutide from Eli Lilly and Novo Nordisk.